Related Experiment Videos
Bladder cancer cells express functional receptors for granulocyte-colony stimulating factor
T Ohigashi1, M Tachibana, H Tazaki
1Department of Urology, School of Medicine, Keio University, Tokyo, Japan.
The Journal of Urology
|January 1, 1992
Summary
Human recombinant granulocyte-colony stimulating factor (G-CSF) significantly enhances bladder cancer cell growth. This growth stimulation occurs via G-CSF binding to specific receptors on cancer cells, indicating a potential therapeutic target.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Investigating the role of growth factors in cancer development is crucial for understanding tumorigenesis.
- Granulocyte-colony stimulating factor (G-CSF) is known for its role in hematopoiesis, but its effects on solid tumors require further elucidation.
Purpose of the Study:
- To determine the effect of human recombinant G-CSF on the proliferation of cultured human bladder cancer cells.
- To investigate the presence and function of G-CSF receptors on these bladder cancer cells.
Main Methods:
- Human bladder cancer cell lines (KU-1 and NBT-2) were cultured with and without varying concentrations of G-CSF.
- Cell proliferation was assessed by measuring 3H-thymidine uptake.
- G-CSF receptor binding was evaluated using 125I-labeled G-CSF mutein (KW-2228) and unlabeled KW-2228 for competitive inhibition assays.
Main Results:
- G-CSF significantly increased 3H-thymidine uptake in both KU-1 and NBT-2 cell lines at 48 hours compared to controls (p < 0.05).
- The binding of labeled G-CSF mutein to cancer cells was dose-dependently inhibited by unlabeled G-CSF, confirming specific receptor interaction.
- These findings indicate that G-CSF receptors are present and functional on human bladder cancer cells.
Conclusions:
- Human recombinant G-CSF stimulates the clonal growth of human bladder cancer cells.
- This proliferative effect is mediated through the specific binding of G-CSF to its receptors on the cancer cells.
- The G-CSF receptor pathway represents a potential target for therapeutic intervention in bladder cancer.